| Title |
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, November 2012
|
| DOI | 10.1007/s10549-012-2328-6 |
| Pubmed ID | |
| Authors |
A. Jo Chien, Hope S. Rugo |
| Abstract |
The widespread use of trastuzumab in the past decade has led to a significant and measureable improvement in the survival of patients with human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer, and in many ways has redefined the natural history of this aggressive breast cancer subtype. Historically, survival in patients with HER2-positive disease was dictated by the systemic disease course, and what appears to be the central nervous system (CNS) tropism associated with HER2-amplified tumors was not clinically evident. With improved systemic control and prolonged survival, the incidence of brain metastases has increased, and CNS disease, often in the setting of well-controlled extracranial disease, is proving to be an increasingly important and clinically challenging cause of morbidity and mortality in patients with HER2-positive advanced breast cancer. This review summarizes the known clinical data for the systemic treatment of HER2-positive CNS metastases and includes information about ongoing clinical trials of novel therapies as well as emerging strategies for early detection and prevention. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 4% |
| South Africa | 1 | 2% |
| Unknown | 53 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 20% |
| Student > Ph. D. Student | 9 | 16% |
| Student > Bachelor | 7 | 13% |
| Other | 6 | 11% |
| Student > Postgraduate | 6 | 11% |
| Other | 13 | 23% |
| Unknown | 4 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 52% |
| Agricultural and Biological Sciences | 6 | 11% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Unspecified | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 6 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2015.
All research outputs
#14,737,988
of 22,685,926 outputs
Outputs from Breast Cancer Research and Treatment
#3,156
of 4,618 outputs
Outputs of similar age
#109,846
of 180,806 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#51
of 65 outputs
Altmetric has tracked 22,685,926 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,618 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,806 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.